CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing genetically engineered T cells from induced pluripotent stem cells for treating Multiple Myeloma. It aims to create broadly applicable T cells that can overcome histocompatibility barriers and enhance therapeutic efficacy.
The feasibility and effectiveness of adoptive T cell therapies for cancer has now been proven in several clinical settings.
Yet, the current approaches are still “individual-tailored” and thus, their progress and broader use is limited.
Having rapid access to “off-the-shelf”, safe cellular products, which can be applied across histocompatibility limitations, would greatly benefit the broader applicability of adoptive T cell therapy.
To this end, the applicant recently reported, in a proof-of-con…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Amsterdam
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
